HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this link to a friend Similar articles in this journal Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Turner, M. R. Articles by Leigh, P. N. Search for Related Content PubMed Articles by Turner, M. R. Articles by Leigh, P. N.

Riluzole and Motor Neurone Disease

Institute of Psychiatry, De Crespigny Park, London, UK; E-mail: n.leigh{at}iop.kcl.ac.uk

EXTRACT

INTRODUCTION

Riluzole is the only agent approved as a disease-modifying treatment for motor neurone disease (MND). It may, or may not (depending on how one views the evidence), modify the rate of disease progression. We will examine the use of this drug that is generally viewed to have at best only a limited impact on survival in a miserable disease. With the general neurologist in mind, we hope to present a balanced view of the available evidence, with thoughts for future research and what we do in our own practice. We will highlight some of the scientific and ethical issues posed by disorders like MND, and the constraints imposed by the priorities of the pharmaceutical industry and state-sponsored research bodies.

WHAT IS THE IDEAL?

What then are the desirable features of a disease-modifying therapy for MND? We propose the following:

• significant increase in survival – at least 4 months (i.e.
  

[PDF of this article]